Anticholinergic medications and risk of dementia in older adults: Where are we now?. Issue 10 (2nd October 2020)

• Record Type: Journal Article
• Authors: Chatterjee, Satabdi; Talwar, Ashna; Aparasu, Rajender R.
• Is Part Of: Expert opinion on drug safety. Volume 19:Issue 10(2020)
• Page Start: 1251
• Page End: 1267
• Publication Date: 2020-10-02
• Subjects: Anticholinergic -- dementia -- older adults; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2020.1811227
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Anticholinergic medications are effective for a wide variety of indications, but are associated with significant central adverse effects, especially cognitive decline and dementia in older adults. Areas covered: We conducted a review of relevant literature in the past decade to address anticholinergic scales and evidence of anticholinergic-related dementia/cognitive decline in older adults. We discussed various anticholinergic scales used to classify anticholinergic medications. The review focused on the evidence from previous reviews and individual studies evaluating the anticholinergic-related risk of developing cognitive decline/dementia. This review also discussed clinical and methodological issues of studies along with recommendations for practice and research. Expert opinion: The review demonstrates moderate to strong risk of dementia with anticholinergic use in multiple studies involving older adults, irrespective of the study design, analytical approach, anticholinergic exposure and outcome definition. This risk is particularly significant with the cumulative burden and high-level anticholinergics. There also exists a dose–response relationship between anticholinergic use and increased risk for dementia. Therefore, anticholinergic agents can be considered as a modifiable risk factor for dementia and cognitive decline in older adults. Based on the current evidence, regular assessment and optimization of anticholinergic burden prior to prescribing these medications can minimize anticholinergic-related morbidity in older adults.